Amir Toor

Amir Toor


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2001 in Blood
Verified
Journal Article
Open access
MZMaurizio Zangari
Maurizio Zangari
EAElias Anaissie
Elias Anaissie
BBBart Barlogie
Bart Barlogie
ABAshraf Badros
Ashraf Badros
RDRaman Desikan
Raman Desikan
GTGuido Tricot
Guido Tricot
The occurrence of deep-vein thrombosis (DVT) in patients with newly diagnosed multiple myeloma, who were randomly assigned to receive identical induction chemotherapy with or without thalidomide, are reported in this study. The 2 study arms were comparable with respect to key myeloma prognostic factors and known risk factors for DVT. One hundred patients received induction chemotherapy including 4 cycles of continuous infusion of combinations of dexamethasone, vincristine, doxorubicin, cyclophosphamide, etoposide, and cisplatin, and each patient completed at least one induction cycle. DVT developed in 14 of 50 patients (28%) randomly assigned to receive thalidomide but in only 2 of 50 patients (4%) not given the agent (P = .002). All episodes of DVT occurred during the first 3 cycles of induction. Administration of thalidomide was resumed safely in 75% of patients receiving anticoagulation therapy. Thus, thalidomide given in combination with multiagent chemotherapy and dexamethasone is associated with a significantly increased risk of DVT, which appears to be safely treated with anticoagulation and does not necessarily warrant discontinuation of thalidomide.

1 December 2004 in Blood
Verified
Journal Article
Closed access
PDF file
CHChristiane Houde
Christiane Houde
YLYulin Li
Yulin Li
LSLynda Song
Lynda Song
KBKevin Barton
Kevin Barton
QZQing Zhang
Qing Zhang
LCLionel J. Coignet
Lionel J. Coignet
The NOTCH ligand, JAG2, was found to be overexpressed in malignant plasma cells from multiple myeloma (MM) patients and cell lines but not in nonmalignant plasma cells from tonsils, bone marrow from healthy individuals, or patients with other malignancies. In addition, JAG2 overexpression was detected in 5 of 5 patients with monoclonal gammopathy of undetermined significance (MGUS), an early phase of myeloma disease progression. This overexpression appears to be a consequence of hypomethylation of the JAG2 promoter in malignant plasma cells. An in vitro coculture assay was used to demonstrate that JAG2 induced the secretion of interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), and insulin-like growth factor-1 (IGF-1) in stromal cells. Further, the induction of IL-6 secretion was blocked in vitro by interference with anti–Notch-1 monoclonal antibodies raised against the binding sequence of Notch-1 with JAG2. Taken together, these results indicate that JAG2 overexpression may be an early event in the pathogenesis of multiple myeloma involving IL-6 production.

1 May 2001 in Blood
Verified
Journal Article
Closed access
ABAshraf Badros
Ashraf Badros
BBBart Barlogie
Bart Barlogie
CMChristopher Morris
Christopher Morris
RDRaman Desikan
Raman Desikan
SMSara R. Martin
Sara R. Martin
GTGuido Tricot
Guido Tricot
Standard allogeneic stem cell transplant (allo-SCT) regimens have been associated with a high transplant-related mortality (TRM) in multiple myeloma (MM). Nonmyeloablative therapy can establish stable engraftment after allo-SCT and maintain the antitumor effect with less toxicity, which is important in heavily pretreated and elderly patients. We report on 16 poor-risk MM patients receiving allo-SCT from an HLA-matched (n = 14) or mismatched (n = 2) sibling following conditioning with melphalan 100 mg/m2 (MEL-100). Ten patients had refractory relapse, 4 responsive relapse, and 2 patients were in near complete remission (nCR) with poor-prognosis disease. Patients had received 1 (n = 9) or 2 (n = 7) prior autotransplants. Donor lymphocyte infusions (DLIs) were given to 14 patients with no clinical evidence of graft versus host disease (GVHD) either to attain full donor chimerism (n = 4) or to eradicate residual disease (n = 10). Fifteen patients showed myeloid engraftment, and 12 patients were full donor chimeras at day +21. No TRM was observed during the first 100 days. Acute GVHD developed in 10 patients; 1 had fatal grade IV GVHD. Seven progressed to chronic GVHD, limited in 3 and extensive in 4 patients. At a median follow-up of 1 year, 5 patients achieved and sustained CR, 3 nCR, and 4 partial remission. Of 4 patients progressing after transplantation, 3 achieved a remission following further chemotherapy and DLI. Remarkable graft versus myeloma responses were seen in chemotherapy-refractory patients. Two patients died of progressive disease, and 3 died of GVHD complications without active disease. GVHD remains a major problem with this procedure.

25 March 2002 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
AFAthanasios B.‐T. Fassas
Athanasios B.‐T. Fassas
FMFiras Muwalla
Firas Muwalla
TBTanya Berryman
Tanya Berryman
RBRiad Benramdane
Riad Benramdane
LJLija Joseph
Lija Joseph
GTGuido Tricot
Guido Tricot

30 August 2002 in Leukemia
Verified
Journal Article
Closed access
NMNc Munshi
Nc Munshi
GTG Tricot
G Tricot
RDR Desikan
R Desikan
ABA Badros
A Badros
MZM Zangari
M Zangari
BBB Barlogie
B Barlogie

1 April 2002 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Closed access
MZM. Zangari
M. Zangari
FSF. Saghafifar
F. Saghafifar
EAE. Anaissie
E. Anaissie
ABA. Badros
A. Badros
RDR. Desikan
R. Desikan
GTG. Tricot
G. Tricot
Thromboembolism is not uncommon in multiple myeloma (MM) patients on treatment, but its pathogenesis remains poorly understood. We report the results of a prospective randomized trial of 62 newly diagnosed MM patients tested at baseline for hypercoagulability and treated with intensive chemotherapy with or without thalidomide in a randomized fashion. During the induction phase, 12 patients (19%) developed evidence of deep venous thrombosis (DVT), which was significantly more common in the thalidomide arm (36%) than in the control group (3%) (P = 0.001). Fourteen patients (23%) were found to have a baseline-reduced response to activated protein C (APC) in the absence of factor V Leiden mutation. Using a Kaplan–Meier analysis, a significantly higher proportion of patients with APC resistance developed DVT (5/14 versus 7/38;P = 0.04) irrespective of thalidomide administration. The risk of DVT was highest (50%) in patients with APC resistance on thalidomide. None of the patients with normal APC response and not receiving thalidomide developed DVT. In conclusion, in this series, acquired APC resistance was present in almost one-quarter of newly diagnosed myeloma patients and significantly increased the risk of DVT.